VXRT:OTCMKTS
Vaxart Inc
0,43 US$
arrow_downward
-0,02%(-0,000075) 1D
9 ოქტ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VXRT...
Open
0,44 US$
High
0,45 US$
Low
0,43 US$
Mkt. cap
106,59 მლნ.
Avg. vol.
265,13 ათ.
Volume
198,22 ათ.
P/E ratio
2,66
52-wk high
0,84 US$
52-wk low
0,30 US$
EPS
0,16 US$
Beta
1,05
Shares outstanding
242,84 მლნ.
No. of employees
65
Open
0,44 US$
High
0,45 US$
Low
0,43 US$
Mkt. cap
106,59 მლნ.
Avg. vol.
265,13 ათ.
Volume
198,22 ათ.
P/E ratio
2,66
52-wk high
0,84 US$
52-wk low
0,30 US$
EPS
0,16 US$
Beta
1,05
Shares outstanding
242,84 მლნ.
No. of employees
65
News stories
From web sources and news partners
Simply Wall Street
·
36 წუთის წინ
EBay (EBAY) Tightens Seller Rules In Australia And The US
MarketBeat
·
25 წუთის წინ
Quantum-Si (NASDAQ:QSI) Stock Rating Raised to "Hold" at Wall Street Zen
MarketBeat
·
25 წუთის წინ
Rush Enterprises (NASDAQ:RUSHA) Rating Lowered to Hold at Wall Street Zen
Yahoo Finance
·
7 საათის წინ
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEOსტივენ ლო
Employees65
Foundedმარ 2004
HeadquartersSouth San Francisco, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitevaxart.com